622 related articles for article (PubMed ID: 18157006)
1. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
2. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
[TBL] [Abstract][Full Text] [Related]
3. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
4. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
[TBL] [Abstract][Full Text] [Related]
7. Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.
Kesarwani P; Chakraborty P; Gudi R; Chatterjee S; Scurti G; Toth K; Simms P; Husain M; Armeson K; Husain S; Garrett-Mayer E; Vasu C; Nishimura MI; Mehrotra S
Oncotarget; 2016 Oct; 7(43):69371-69383. PubMed ID: 27750220
[TBL] [Abstract][Full Text] [Related]
8. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
9. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
Yang S; Cohen CJ; Peng PD; Zhao Y; Cassard L; Yu Z; Zheng Z; Jones S; Restifo NP; Rosenberg SA; Morgan RA
Gene Ther; 2008 Nov; 15(21):1411-23. PubMed ID: 18496571
[TBL] [Abstract][Full Text] [Related]
10. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
11. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
12. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
[TBL] [Abstract][Full Text] [Related]
14. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
16. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
19. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
Clay TM; Custer MC; Spiess PJ; Nishimura MI
Pathol Oncol Res; 1999; 5(1):3-15. PubMed ID: 10079371
[TBL] [Abstract][Full Text] [Related]
20. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
Overwijk WW; Theoret MR; Finkelstein SE; Surman DR; de Jong LA; Vyth-Dreese FA; Dellemijn TA; Antony PA; Spiess PJ; Palmer DC; Heimann DM; Klebanoff CA; Yu Z; Hwang LN; Feigenbaum L; Kruisbeek AM; Rosenberg SA; Restifo NP
J Exp Med; 2003 Aug; 198(4):569-80. PubMed ID: 12925674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]